東寶生物(300239.SZ):於建華、賀志賢及賈利明擬合計減持不超16.3萬股
格隆匯5月20日丨東寶生物(300239.SZ)公佈,近日,公司收到監事會主席於建華、監事賀志賢出具的《關於減持計劃時間屆滿暨新的減持計劃吿知函》,於建華、賀志賢前次減持計劃時間屆滿,併發起新的減持計劃。同時公司收到副總經理賈利明出具的《關於股份減持計劃吿知函》。
於建華擬減持公司股份數量不超過2.15萬股,不超過其持有公司股份總數的25%,即不超過公司總股本的0.0041%;
賀志賢擬減持股份數量不超過12.43萬股,不超過其持有公司股份總數的25%,即不超過公司總股本的0.0238%;
賈利明擬減持股份數量不超過1.72萬股,不超過其持有公司股份總數的25%,即不超過公司總股本的0.0033%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.